HK1121235A1 - Methods of modulating cell surface receptors to prevent or reduce inflammation - Google Patents

Methods of modulating cell surface receptors to prevent or reduce inflammation

Info

Publication number
HK1121235A1
HK1121235A1 HK09101087.3A HK09101087A HK1121235A1 HK 1121235 A1 HK1121235 A1 HK 1121235A1 HK 09101087 A HK09101087 A HK 09101087A HK 1121235 A1 HK1121235 A1 HK 1121235A1
Authority
HK
Hong Kong
Prior art keywords
species
methods
bacterium
agent
prevent
Prior art date
Application number
HK09101087.3A
Other languages
English (en)
Inventor
Prem Sreenivasan
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38017086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1121235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of HK1121235A1 publication Critical patent/HK1121235A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
HK09101087.3A 2006-01-10 2009-02-06 Methods of modulating cell surface receptors to prevent or reduce inflammation HK1121235A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75775106P 2006-01-10 2006-01-10
PCT/US2007/060222 WO2007082181A2 (en) 2006-01-10 2007-01-08 Methods of modulating cell surface receptors to prevent or reduce inflammation

Publications (1)

Publication Number Publication Date
HK1121235A1 true HK1121235A1 (en) 2009-04-17

Family

ID=38017086

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09101087.3A HK1121235A1 (en) 2006-01-10 2009-02-06 Methods of modulating cell surface receptors to prevent or reduce inflammation
HK10108234.7A HK1141838A1 (en) 2006-01-10 2010-08-30 Methods of modulating cell surface receptors to prevent or reduce inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK10108234.7A HK1141838A1 (en) 2006-01-10 2010-08-30 Methods of modulating cell surface receptors to prevent or reduce inflammation

Country Status (18)

Country Link
US (1) US9157914B2 (de)
EP (2) EP1971865B1 (de)
JP (2) JP2009523029A (de)
CN (1) CN101371141A (de)
AR (1) AR058959A1 (de)
AU (1) AU2007204730B2 (de)
BR (1) BRPI0706505A2 (de)
CA (2) CA2849559A1 (de)
DK (2) DK2177621T3 (de)
ES (2) ES2431291T3 (de)
HK (2) HK1121235A1 (de)
MY (1) MY151118A (de)
PH (1) PH12014501163A1 (de)
PL (2) PL2177621T3 (de)
RU (1) RU2431845C2 (de)
TW (2) TW201415028A (de)
WO (1) WO2007082181A2 (de)
ZA (1) ZA200805730B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431291T3 (es) * 2006-01-10 2013-11-25 Colgate-Palmolive Company Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación
CN102378629B (zh) 2009-04-01 2016-08-17 高露洁-棕榄公司 用于口部护理组合物的抗生物膜碳酸酯化合物
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
AR076041A1 (es) 2009-04-01 2011-05-11 Colgate Palmolive Co Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
JP5550717B2 (ja) 2009-04-01 2014-07-16 コルゲート・パーモリブ・カンパニー メントール誘導体ならびに口腔活性剤および全身活性剤としてのそれらの使用
MX2017014196A (es) 2015-05-06 2018-03-01 Procter & Gamble Deteccion de factores de virulencia microbiana bucal.
US9964472B2 (en) 2016-06-29 2018-05-08 The Procter & Gamble Company Methods for sampling gingival metabolites
MX2022011974A (es) * 2020-04-02 2022-10-20 Colgate Palmolive Co Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538230A (en) * 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4358437A (en) * 1978-11-29 1982-11-09 Beecham Group Limited Compositions
US5288480A (en) * 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
GB9117140D0 (en) * 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
DE4226043A1 (de) * 1992-08-06 1994-02-10 Haarmann & Reimer Gmbh Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen
WO1995013094A1 (en) 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5578295A (en) * 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
US6482418B1 (en) 1996-06-12 2002-11-19 Henkel Kommanditgesellschaft Auf Aktien Cosmetic and/or pharmaceutical preparations comprising dialkenyl carbonates
EP0863402B1 (de) 1997-03-03 2005-09-14 Amersham Biosciences UK Limited In-situ Zellextraktion und Assay-Verfahren
JP2000128900A (ja) 1998-10-26 2000-05-09 Japan Science & Technology Corp 新規トル様（Ｔｏｌｌ−ｌｉｋｅ）レセプター及びその遺伝子
FR2794457B1 (fr) 1999-06-01 2001-08-10 Oreal Derives carbonates de retinol, procede de preparation et utilisations
DK2295968T3 (da) * 1999-12-03 2012-12-17 Baxter Healthcare Sa Pyrogenicitetsprøve til anvendelse i forbindelse med automatiserede immunanalysesystemer
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6500409B1 (en) 2000-05-10 2002-12-31 Colgate Palmolive Company Synergistic antiplaque/antigingivitis oral composition
DE10059584A1 (de) 2000-11-30 2002-06-06 Beiersdorf Ag Kosmetische oder dermatologische getränkte Tücher
PL366250A1 (en) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
NZ530764A (en) 2001-07-09 2008-07-31 Combinatorx Inc Composition comprising a tricyclic antidepressant and a corticosteroid administered simutaneously or within 14 days for treatment of inflammatory disorders
US6893828B2 (en) 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
EP1499898A2 (de) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulierung von tnf-alpha
US7005225B2 (en) * 2002-11-12 2006-02-28 Samsung Electronics Company Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
GB2401865A (en) 2003-05-22 2004-11-24 Givaudan Sa Antibacterial and antifungal glycerol monocarbonates
EP1697389A4 (de) 2003-10-24 2008-12-24 Eisai R&D Man Co Ltd Verbindungen und verfahren zur behandlung von mit dem toll-like receptor 2 in zusammenhang stehenden krankheiten und leiden
ES2320139T3 (es) * 2003-12-03 2009-05-19 Whitehead Institute For Biomedical Research Uso de t-cadherina soluble para el tratamiento de trastornos metabolicos.
JP2005304365A (ja) 2004-04-20 2005-11-04 Japan Science & Technology Agency Ｔｌｒリガンド及びｉｌ−１応答障害性モデル動物
FI20040572A0 (fi) 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
US20060141421A1 (en) * 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. System and method for detecting substances related to oral health
WO2006074450A2 (en) * 2005-01-07 2006-07-13 President And Fellows Of Harvard College Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
ES2431291T3 (es) * 2006-01-10 2013-11-25 Colgate-Palmolive Company Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación
US20080161394A1 (en) 2006-11-23 2008-07-03 Jean-Yves Fouron Cosmetic composition comprising at least one volatile carbonic acid ester
WO2008093072A2 (en) 2007-01-29 2008-08-07 Paul Webb Topical composition against contact dermatitis due to water
EP2207546A1 (de) 2007-10-09 2010-07-21 Humco Holding Group, Inc. Antimykotische nagelbehandlung

Also Published As

Publication number Publication date
EP2177621B1 (de) 2013-10-09
RU2008132839A (ru) 2010-02-20
ES2421595T3 (es) 2013-09-04
AU2007204730B2 (en) 2011-11-17
US20070160544A1 (en) 2007-07-12
HK1141838A1 (en) 2010-11-19
ZA200805730B (en) 2014-12-23
AU2007204730A1 (en) 2007-07-19
MY151118A (en) 2014-04-15
PL2177621T3 (pl) 2014-03-31
PH12014501163A1 (en) 2015-05-18
JP2009523029A (ja) 2009-06-18
EP2177621A2 (de) 2010-04-21
PL1971865T3 (pl) 2014-02-28
CN101371141A (zh) 2009-02-18
BRPI0706505A2 (pt) 2011-03-29
ES2431291T3 (es) 2013-11-25
CA2635605C (en) 2014-07-08
AR058959A1 (es) 2008-03-05
WO2007082181A2 (en) 2007-07-19
JP2015051000A (ja) 2015-03-19
DK2177621T3 (da) 2013-10-28
TW200801514A (en) 2008-01-01
EP1971865B1 (de) 2013-04-17
TW201415028A (zh) 2014-04-16
EP1971865A2 (de) 2008-09-24
US9157914B2 (en) 2015-10-13
DK1971865T3 (da) 2013-07-08
WO2007082181A3 (en) 2007-09-27
CA2849559A1 (en) 2007-07-19
EP2177621A3 (de) 2010-09-08
CA2635605A1 (en) 2007-07-19
RU2431845C2 (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
PH12014501163A1 (en) Methods of modulating cell surface receptors to prevent or reduce inflammation
ATE539165T1 (de) Verfahren zum nachweis von beta-lactamase
CL2009002114A1 (es) Un método para detectar al menos un olor en una muestra de gas que comprende: reducir, al menos parcialmente, una cantidad de agua en la muestra de gas; y detectar la presencia o ausencia de olor en la muestra; se describe además un aparato para detectar y/o medir olores en una muestra de gas.
TW200731182A (en) Display devices with ambient light sensing
GB0615692D0 (en) System for counting bacteria and determining their susceptibility to antibiotics
GB2477877A (en) Colorimetric test for brake system corrosion
WO2008008257A3 (en) Oriented magnetic particle-fluorescence detectable moiety compositions and methods of making and using the same
WO2007092864A3 (en) Calibration arrangement for breath testing equipment
DE602006004726D1 (de) Fahrzeugzündsperrsysteme mit mundalkoholverunreinigungssensor
GB2435328B (en) Methods and device for indirectly detecting the presence of an analyte
WO2008027098A3 (en) Biosensor for measurement of species in a body fluid
GB0620504D0 (en) Method
TW200641137A (en) A method for quantifying cholesterol of remnant-like particles lipoprotein, reagent and kit
FI20055231A (fi) Menetelmä ja mittalaite mitata vesipitoisuutta
EP2067027B8 (de) Mikrosensor zum nachweis von d-aminosäuren
TW200744021A (en) Paper money processing device
CY1110518T1 (el) Συνθεση για την καταπολεμηση του ροχαλισματος
HK1114574A1 (en) Acidic solid oral compositions without erosive potential in saliva and method for determining erosive potential in saliva
CL2008002075A1 (es) Metodo para detectar cancer o precancer en una persona que comprende determinar una primera relacion de un nivel de microsatelites de adn presentes en un segundo alelo de una celula epitelial bucal de una persona; conjunto de cebadores para detectar una mutacion de adn.
AU2001282807A1 (en) Method and device for detecting ozone consuming agents
ATE527524T1 (de) Plombe zur sicherung eines energieverbrauchmessgeräts
TW200724307A (en) Wear monitoring system for a conveyor and method thereof
FR2920772B1 (fr) Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine
TH99220A (th) วิธีของการปรับตัวรับพื้นผิวเซลล์เพื่อป้องกันหรือลดการอักเสบ
MXPA04006361A (es) Un ensayo de deteccion de proteinas del tipo tirosina fosfatasas (ptpasas) continuo y altamente sensible que usa fosfato de 6,8-difluoro-4-metilumbeliferilo.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170108